Scientists have created new compounds (fluorophores) for photodynamic therapy of cancerous tumors. They interact with the biomolecules of body tissues and, under ultraviolet or visible irradiation, stain areas in which the process of tumor growth is underway. The compound is suitable both for the diagnosis of tumor processes and for their further treatment.

A new consortium for the advancement of Proton Online Adaptive Radiation Therapy, ProtOnART, uniquely brings together researchers, clinicians, and industry. The members of the ProtOnART consortium are OncoRay in Dresden, Germany, and PARTICLE in Leuven, Belgium, both combining academic expertise with clinical experience in proton therapy, as well as industrial partners Ion Beam Applications (IBA), proton therapy system manufacturer from Belgium, and RaySearch Laboratories, provider of oncology software solutions from Sweden.

Single-cell RNA sequencing (scRNA-seq) is one of the most important methods to study biological function in cells, but it is limited by potential inaccuracies in the data it generates. Now, a research team from Japan has developed a new method called terminator-assisted solid-phase complementary DNA amplification and sequencing (TAS-Seq), which overcomes these limitations and provides higher-precision data than existing scRNA-seq platforms.

Hormone therapy is successful at keeping metastatic prostate cancer under control, but eventually the tumor cells become resistant to it. An unexpected potential solution has now emerged in medicines not designed to fight cancer, but to target proteins that regulate a cell’s circadian rhythm. An international team of researchers led by the Netherlands Cancer Institute will publish this discovery on June 27, 2022, in the renowned journal Cancer Discovery, a journal of the American Association for Cancer Research.

A new study from the Tokyo University of Agriculture and Technology shows a method for detecting microRNA expression patterns using nanopore-based DNA computing technology. The information of miRNAs from bile duct cancer is encoded in diagnostic DNAs and decoded electrically by nanopore analysis. With this system, they succeeded in label-free detection of miRNA expression patterns from the plasma of bile duct cancer patients.

biodegradable nanomaterials that will take pictures and deliver medicine to combat peripheral arterial disease (PAD). Kytai Nguyen, a UT Arlington bioengineering professor, is the principal investigator in the four-year, $2.1 million National Institutes of Health (NIH) grant.

Collaborative research groups have found that glycerol phosphate modification of glycans is exhibited in various cancer tissues, and this modification disrupts glycan-mediated cell adhesion, thereby promoting the migration of cancer cells. Their findings can contribute to the development of cancer therapies targeting this modification.

A research group led by Osaka Metropolitan University unveiled the mechanism by which proteins that trigger cancer development are released in liver cancer associated with high-fat diets. Examinations in cancer-prone mice showed that the proteins IL-1β and IL-33, senescence-associated secretory phenotype (SASP) factors, were exported through cell membrane pores formed by gasdermin D-N. Such pore formation was facilitated by the accumulation of lipoteichoic acid in the liver owing to the gut barrier dysfunction caused by long-term high-fat diets. These findings pave the way for therapeutic strategies that prevent and suppress obesity-associated liver cancer.